文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

如何治疗成人骨髓增生异常肿瘤的铁过载

How I treat iron overload in adult MDS.
PubMed 文献 · Blood · 2025-01-01

本文综述了成人骨髓增生异常肿瘤(MDS)伴铁过载(IOL)的机制、诊断与严重度定义,并基于 illustrative 病例提出铁螯合治疗(ICT)的获益人群、药物选择及监测管理策略。文中指出约50%的MDS患者最终会依赖红细胞输注并发生输血性铁过载,部分预期寿命较长的患者可考虑ICT。

要点

  • 约50%的MDS患者最终会依赖红细胞输注并发生输血性铁过载。
  • 预期寿命合理的MDS伴铁过载患者可考虑铁螯合治疗。
  • 启动螯合治疗需考虑铁蓄积速率、器官铁沉积或功能障碍及氧化应激指标。

核心结论

  • 预期寿命合理的MDS伴铁过载患者可考虑铁螯合治疗。
  • 启动螯合治疗需综合考虑铁蓄积速率、器官铁沉积或功能障碍及可检测的氧化应激指标。

研究设计与样本

  • 本文为综述,通过 illustrative 病例总结铁毒性机制、铁过载识别策略并提出铁过载严重度定义。

主要发现

  • 约50%的MDS患者最终会依赖红细胞输注并发生输血性铁过载。
  • refined prognostication 可识别预期寿命合理的MDS患者。
  • 遗传性贫血(如重型α地中海贫血)中ICT的临床获益确凿,但在输血依赖的MDS伴铁过载患者中证据有时存在争议。

关键数值与推荐

  • 提出了铁过载严重度的定义。
  • 建议根据铁蓄积速率、器官铁沉积或功能障碍及可检测的氧化应激指标来规划螯合治疗的启动。

临床怎么用

  • 对预期寿命合理的MDS伴铁过载患者可考虑铁螯合治疗。
  • 启动螯合治疗前应评估铁蓄积速率、器官铁沉积或功能障碍及氧化应激指标。
  • 文中讨论了现有螯合剂的使用、监测、副作用及其管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although clinical benefits of iron chelation therapy (ICT) in red blood cell (RBC) transfusion-dependent (TD) hereditary anemias such as α-thalassemia major are incontrovertible, the evidence supporting a similar benefit in patients with TD myelodysplastic neoplasms (MDS) and iron overload (IOL) is sometimes debated. MDS presents later in life, has a limited repertoire of life-extending therapies, and patients may have comorbidities acting as competing causes of death. However, refined prognostication identifies patients with MDS with a reasonable life expectancy, and because 50% of patients will ultimately become RBC TD and develop transfusional IOL, ICT should be considered in some. Using illustrative cases, we summarize mechanisms of iron toxicity, strategies for the identification of IOL, and propose definitions of IOL severity. We provide rationale for, and recommend which patients may benefit from, ICT. We discuss currently available chelators, their administration, monitoring, side effects, and their management. Given challenges with the use of iron chelators, we suggest the nuances to be considered when planning chelation initiation to include the rate of iron accumulation, the presence of organ iron and/or dysfunction, and detectable indicators of oxidative stress. Areas for future investigation are identified.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leitch HA, Buckstein R. How I treat iron overload in adult MDS. Blood. 2025. PMID: 38941618. doi:10.1182/blood.2023022501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。